title: Targeted anti-vascular therapies for ovarian cancer: current evidence.
abstract: Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.
authors: Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK. marcia.hall@nhs.net
authors: M
authors: M
authors: Hall
authors: C
authors: C
authors: Gourley
authors: I
authors: I
authors: McNeish
authors: J
authors: J
authors: Ledermann
authors: M
authors: M
authors: Gore
authors: G
authors: G
authors: Jayson
authors: T
authors: T
authors: Perren
authors: G
authors: G
authors: Rustin
authors: S
authors: S
authors: Kaye
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D042682:Angiopoietins / Q000037:antagonists & inhibitors; D043168:Angiostatins / Q000096:biosynthesis; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001632:Bibenzyls / Q000627:therapeutic use; D005260:Female; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors; D005419:Flavonoids / Q000627:therapeutic use; D006801:Humans; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000401:mortality; D019699:Thrombospondins / Q000096:biosynthesis; D016896:Treatment Outcome; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042682:Angiopoietins; D061067:Antibodies, Monoclonal, Humanized; D001632:Bibenzyls; D005419:Flavonoids; D019699:Thrombospondins; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D005346:Fibroblast Growth Factors; C040105:combretastatin; D043168:Angiostatins; C049328:flavone acetic acid
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: Ann Oncol. 2011 Feb;22(2):335-40
references: 20705911
references: N Engl J Med. 2011 Dec 29;365(26):2484-96
references: 22204725
references: Clin Lung Cancer. 2011 May;12(3):143-7
references: 21663855
references: J Cancer Res Clin Oncol. 2010 May;136(5):737-43
references: 19904559
references: Gynecol Oncol. 2006 Jul;102(1):49-53
references: 16375951
references: Ann Oncol. 2012 Feb;23(2):346-52
references: 21562072
references: Int J Gynecol Cancer. 2011 May;21 Suppl 1:S12-6
references: 21540666
references: J Clin Oncol. 2011 Jan 1;29(1):69-75
references: 21098323
references: J Clin Oncol. 2009 Nov 20;27(33):5601-6
references: 19826113
references: J Cell Biol. 1995 Aug;130(3):503-6
references: 7542656
references: Gynecol Oncol. 2007 Apr;105(1):3-6
references: 17383545
references: Gynecol Oncol. 2007 Nov;107(2):326-30
references: 17706754
references: Cancer Cell. 2009 Mar 3;15(3):232-9
references: 19249681
references: J Clin Oncol. 2008 Jan 1;26(1):76-82
references: 18165643
references: J Clin Oncol. 2014 May 1;32(13):1302-8
references: 24637997
references: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references: 17442997
references: J Clin Oncol. 2011 Jan 1;29(1):83-8
references: 21098326
references: Gynecol Oncol. 2009 Sep;114(3):424-6
references: 19552944
references: Ann Oncol. 2012 May;23(5):1130-1137
references: 21976387
references: Oncologist. 2009 Dec;14(12):1242-51
references: 20008305
references: J Clin Oncol. 2012 Feb 1;30(4):362-71
references: 22184370
references: Ann Oncol. 2011 Sep;22(9):2036-2041
references: 21273348
references: J Clin Oncol. 2011 Apr 1;29(10):1230-2
references: 21383287
references: J Clin Oncol. 2011 Oct 1;29(28):3798-804
references: 21859991
references: J Clin Oncol. 2001 Feb 15;19(4):1195-206
references: 11181686
references: Clin Breast Cancer. 2012 Feb;12(1):10-8
references: 22154153
references: Lancet. 2009 Oct 17;374(9698):1331-8
references: 19767092
references: Gynecol Oncol. 2010 Oct;119(1):32-7
references: 20584542
references: Cochrane Database Syst Rev. 2011 Sep 07;(9):CD007930
references: 21901715
references: Clin Cancer Res. 1996 Nov;2(11):1843-9
references: 9816139
references: Br J Cancer. 2003 Apr 22;88(8):1160-7
references: 12698178
references: N Engl J Med. 2011 Dec 29;365(26):2473-83
references: 22204724
references: Cancer. 2013 Feb 1;119(3):648-55
references: 22893596
references: Semin Oncol. 2011 Aug;38(4):521-32
references: 21810511
references: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references: 18024863
references: Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24
references: 14613032
references: Gynecol Oncol. 2010 Mar;116(3):374-7
references: 19922988
references: Gynecol Oncol. 2011 May 1;121(2):269-72
references: 21315428
references: J Clin Oncol. 2007 Nov 20;25(33):5180-6
references: 18024865
references: Cancer Res. 2005 Mar 15;65(6):2433-40
references: 15781659
references: Gynecol Oncol. 2009 Dec;115(3):396-400
references: 19804901
references: Eur J Cancer. 2012 Mar;48(4):475-81
references: 22196033
references: Eur J Cancer. 2012 May;48(8):1126-32
references: 22424880
references: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references: 22529265
references: Mol Cancer Ther. 2010 Apr;9(4):985-95
references: 20371710
references: Br J Hosp Med (Lond). 2010 Dec;71(12):670-7
references: 21135762
references: Vascul Pharmacol. 2010 Sep-Oct;53(3-4):115-21
references: 20470900
references: Gynecol Oncol. 2010 Mar;116(3):335-9
references: 20004956
references: J Clin Oncol. 2008 Nov 20;26(33):5326-34
references: 18854571
references: Gynecol Oncol. 2010 Jul;118(1):47-51
references: 20382413
references: Cancer Chemother Pharmacol. 2012 Oct;70(4):575-81
references: 22886005
references: Mol Cancer Ther. 2010 Apr;9(4):996-1006
references: 20371722
references: J Clin Oncol. 2011 May 1;29(13):1757-64
references: 21422411
references: Cancer Res. 2006 Dec 15;66(24):11520-39
references: 17178843
references: Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16
references: 15934498